The effect of endothelin receptor antagonists on vasospasm following aneurysmal subarachnoid hemorrhage

Neurosurgery

Volumn 69, Issue 6, 2011, Pages

  Komotar, Ricardo J ^a   Starke, Robert M ^a   Connolly, E Sander ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLAZOSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ANEMIA; BRAIN INFARCTION; CALCIUM CELL LEVEL; DISEASE SEVERITY; HUMAN; HYPOTENSION; LUNG DISEASE; NERVE CELL LESION; NOTE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; TREATMENT RESPONSE; VASOSPASM;

DIOXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PYRIDINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; VASOSPASM, INTRACRANIAL;

EID: 80955159844     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.neu.0000407918.14115.e5     Document Type: Note

References (24)

1. Yung LM, Leung FP, Yao X, Chen ZY, Huang Y. Reactive oxygen species in vascular wall. Cardiovasc Hematol Disord Drug Targets. 2006;6(1):1-19. (Pubitemid 43803123)
2. Hingorani AD, Liang CF, Fatibene J, et al. A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999; 100(14):1515-1520. (Pubitemid 29461463)
3. Kuhlencordt PJ, Gyurko R, Han F, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001;104(4):448-454. (Pubitemid 32678276)
4. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. Neurosurgery. 2003; 53(1):123-133; discussion 133-135.
5. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(2):109-142.
6. Kolias AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: Putative mechanisms and novel approaches. J Neurosci Res. 2009;87(1):1-11.
7. Pluta RM, Afshar JK, Thompson BG, Boock RJ, Harvey-White J, Oldfield EH. Increased cerebral blood flow but no reversal or prevention of vasospasm in response to L-arginine infusion after subarachnoid hemorrhage. J Neurosurg. 2000;92(1):121-126. (Pubitemid 30022095)
8. Pluta RM, Thompson BG, Dawson TM, Snyder SH, Boock RJ, Oldfield EH. Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg. 1996;84(4):648-654. (Pubitemid 26104234)
9. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2000;92(3):390-400. (Pubitemid 30112378)
10. Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: A meta-analysis. Stroke. 2009;40(10):3403-3406.
11. Levin ER. Endothelins. N Engl J Med. 1995;333(6): 356-363.
12. Lovenberg W, Miller RC. Endothelin: A review of its effects and possible mechanisms of action. Neurochem Res. 1990;15(4):407-417. (Pubitemid 20198301)
13. Kobayashi H, HayashiM, Kobayashi S, et al. Cerebral vasospasm and vasoconstriction caused by endothelin. Neurosurgery. 1991;28(5):673-678; discussion 678-679.
14. Xie A, Aihara Y, Bouryi VA, et al. Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2007; 27(10):1692-1701. (Pubitemid 47476098)
15. Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: An overview. Neurosurgery. 1998 43 4):863-875; discussion (Pubitemid 28436337)
16. Zuccarello M, Boccaletti R, Romano A, Rapoport RM. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 1998;29(9):1924-1929. (Pubitemid 28399991)
17. Zuccarello M, Lewis AI, Rapoport RM. Endothelin ETA and ETB receptors in subarachnoid hemorrhage- induced cerebral vasospasm. Eur J Pharmacol. 1994;259(1):R1-R2.
18. Kasuya H, Weir BK, White DM, Stefansson K. Mechanism of oxyhemoglobin-induced release of endothelin-1 from cultured vascular endothelial cells and smooth-muscle cells. J Neurosurg. 1993;79(6): 892-898. (Pubitemid 23342454)
19. Asano T, Ikegaki I, Suzuki Y, Satoh S, Shibuya M. Endothelin and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun. 1989; 159(3):1345-1351. (Pubitemid 19101130)
20. Zubkov AY, Rollins KS, Parent AD, Zhang J, Bryan RM Jr. Mechanism of endothelin-1-induced contraction in rabbit basilar artery. Stroke. 2000;31 (2):526-533. (Pubitemid 30078192)
21. Zimmermann M, Seifert V. [Prevention of cerebral vasospasms after experimental subarachnoid hemorrhage by the endothelin receptor antagonist RO 47-0203]. Zentralbl Neurochir. 1996;57(3): 143-149. (Pubitemid 26265449)
22. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-blind, placebocontrolled, multicenter phase IIa study. J Neurosurg. 2005;103(1):9-17. (Pubitemid 43193928)
23. Macdonald RL. Clazosentan: An endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage. Expert Opin Investig Drugs. 2008;17(11):1761-1767.
24. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomised, double- blind, placebo-controlled phase 3 trial (CONSCIOUS- 2). Lancet Neurol. 2011;10(7):618-625.